Compared directly to Synvisc-One®, DUROLANE reduced pain more effectively.‡4

In a randomised study, there was a significantly greater reduction in visual analog scale (VAS) pain scores at 3 and 6 months with DUROLANE compared to Synvisc-One (hylan G-F 20) (p<0.001).4

DUROLANE showed:

  • 41% lower VAS pain score at 6 months vs. Synvisc-One (hylan G-F 20).
  • Only DUROLANE maintained a significant reduction vs. baseline at 6 months

Some patients were treated with a three-injection Synvisc® regimen. A three-injection Synvisc regimen is equivalent to one injection of Synvisc-One.

Synvisc and Synvisc-One are registered trademarks of Genzyme Biosurgery.


Delay Knee Replacement

A retrospective analysis of 50,349 US patients has shown that hyaluronic acid injections increased time to total-knee-replacement surgery in a treatment course-dependent manner.9 Patients who received ≥ 5 courses of hyaluronic acid treatment delayed total-knee-replacement surgery by 3.6 years.9

A second retrospective analysis, of 224 patients in Spain, showed that treatment with DUROLANE increased the time to surgery of all patients up to 1.5-fold – 1093 days with DUROLANE treatment compared to 694 days without.*10

*Two-hundred and two patients were treated with DUROLANE compared to 22 who did not receive DUROLANE.

Compared directly to steroids injections, DUROLANE relieved pain longer.2

In a Level 1 study:

  • DUROLANE was proven to be noninferior to steroid at 6 weeks.§
  • Results favored DUROLANE for reduction in WOMAC pain, function and stiffness scores from weeks 12 to 26.
  • A significant reduction from baseline to week 26 in WOMAC pain scores was achieved with DUROLANE vs steroid.

Effect-sizes for WOMAC domains with 95% CIs during the blinded phase of the study.

§The primary outcome was the WOMAC pain responder rate, defined as at least 40% relative improvement and 5-point absolute improvement from baseline values at 12 weeks.


Significantly Improved Quality of Life

A single injection of DUROLANE significantly improved all Knee and Osteoarthritis Outcome Score (KOOS) parameters in as early as 2 weeks, and the improvements persisted for up to 24 weeks.5